Article Text
Commentary
Chemokines in colitis: microRNA control
Statistics from Altmetric.com
Footnotes
-
Contributors IR and MBD wrote the initial drafts of the commentary. CTV and BFV edited the initial draft and provided information on chemokine structure to the commentary.
-
Competing interests The use of recombinant CXCL12 as an antimetastatic drug is protected by US Patent 8 404 640 to MBD. BFV and MBD as co-founders of Protein Foundry, LLC, a manufacturer of molecular grade chemokines for use in biomedical research.
-
Provenance and peer review Commissioned; internally peer reviewed.